Opiant Pharmaceuticals said this week it will launch a pivotal pharmacokinetics trial for its OPNT003 (nalmefene nasal spray) opioid overdose candidate in the second quarter—a key priority for the company this year, along with advancing its other pipeline candidates for opioid use disorder, alcohol use disorder, and acute cannabinoid overdose.

The study is expected to generate pivotal PK data in the second half of this year, Opiant disclosed in an investor presentation—data that the company hopes will be positive enough to underpin an NDA . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge